Syapse announced today the commercial launch of Discovery,
its cloud-based application for making omics data actionable in clinical
research and development. Discovery combines a powerful platform
for aggregating and structuring biomedical data with intuitive data
mining, workflow, and reporting features, enabling biopharma and
diagnostics companies to leverage the increasing amount of data
generated by advanced omics technologies such as next-generation
sequencing.
"Syapse Discovery is a powerful solution for harnessing the
large volumes of disparate data types we generate," said Ron
Collette, Chief Information Officer for Foundation Medicine, a molecular
information company whose next-generation sequencing technology for
cancer helps doctors match patients with relevant targeted therapies and
clinical trials. "Syapse Discovery provides a valuable platform
for understanding data and quality metrics, which is important for
continual technology enhancement."
Discovery is used by next-generation sequencing-based
molecular diagnostics companies to organize their R&D data and
processes, and gain the insights necessary to develop and deliver their
diagnostic tests. By bringing together omics and clinical data, Discovery
helps biopharma companies apply omics-based inclusion/exclusion criteria
to clinical trials and assess how cohorts are responding.
"Syapse Discovery is the critical data hub for our
multi-platform diagnostic test for heritable diseases," said Sean
George, Co-founder and CEO of Locus Development. "Discovery helps
us organize and integrate our research, clinical lab, and data analysis
efforts, enabling us to deliver our test results faster. The platform's
flexibility allowed us to customize it for our needs, and rapidly
integrate with a variety of existing automation and databases."